The administration of influenza vaccines remains the most effective way to prevent seasonal influenza. However, vaccines have been known to provide suboptimal protection in high-risk groups. Moreover, they may be ineffective when there is an antigenic mismatch among viruses in the seasonal vaccine and those circulating in the community. Comparatively, antiviral drugs for influenza typically remain effective against antigenic drift variants or newly emerged pandemic viruses, as they target highly stable or conserved components of the virus. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor, baloxavir marboxil. This CME activity evaluates emerging and recently approved antiviral agents with respect to their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding. A provider–patient video highlights the importance of patient assessment and shared decision-making.